Advertisement
Screener

iSpecimen Inc. (ISPC) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

iSpecimen Inc. Comprehensive Income

iSpecimen Inc. (ISPC) reported Comprehensive Income of -$10.49 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-01.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-04-01

  • iSpecimen Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$5.00M.
  • iSpecimen Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$2.78M.
  • iSpecimen Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-06-30 was -$1.05M.
  • iSpecimen Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-03-31 was -$1.66M.
  • iSpecimen Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$10.49M.
  • iSpecimen Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$12.50M.
  • iSpecimen Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$11.10M.
  • iSpecimen Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$10.25M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month
2025-12-31-$5.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01
-$7.78M
derived: sum of 2 quarters · filed 2026-04-01
-$8.83M
derived: sum of 3 quarters · filed 2026-04-01
-$10.49M
10-K · filed 2026-04-01
2025-09-30-$2.78M
10-Q · filed 2025-11-17
-$3.83M
derived: sum of 2 quarters · filed 2025-11-17
-$5.49M
10-Q · filed 2025-11-17
-$11.53M
derived: sum of 4 quarters · filed 2026-04-01
2025-06-30-$1.05M
10-Q · filed 2025-08-14
-$2.71M
10-Q · filed 2025-08-14
-$8.75M
derived: sum of 3 quarters · filed 2026-04-01
-$10.19M
derived: sum of 4 quarters · filed 2026-04-01
2025-03-31-$1.66M
10-Q · filed 2025-05-19
-$7.71M
derived: sum of 2 quarters · filed 2026-04-01
-$9.15M
derived: sum of 3 quarters · filed 2026-04-01
-$11.25M
derived: sum of 4 quarters · filed 2026-04-01
2024-12-31-$6.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01
-$7.49M
derived: sum of 2 quarters · filed 2026-04-01
-$9.60M
derived: sum of 3 quarters · filed 2026-04-01
-$12.50M
10-K · filed 2026-04-01
2024-09-30-$1.44M
10-Q · filed 2025-11-17
-$3.55M
derived: sum of 2 quarters · filed 2025-11-17
-$6.45M
10-Q · filed 2025-11-17
-$9.52M
derived: sum of 4 quarters · filed 2025-11-17
2024-06-30-$2.11M
10-Q · filed 2025-08-14
-$5.01M
10-Q · filed 2025-08-14
-$8.08M
derived: sum of 3 quarters · filed 2025-08-14
-$10.20M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$2.90M
10-Q · filed 2025-05-19
-$5.98M
derived: sum of 2 quarters · filed 2025-05-19
-$8.09M
derived: sum of 3 quarters · filed 2025-05-19
-$11.59M
derived: sum of 4 quarters · filed 2025-05-19
2023-12-31-$3.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-14
-$5.18M
derived: sum of 2 quarters · filed 2025-04-14
-$8.69M
derived: sum of 3 quarters · filed 2025-04-14
-$11.10M
10-K · filed 2025-04-14
2023-09-30-$2.11M
10-Q · filed 2024-11-07
-$5.61M
derived: sum of 2 quarters · filed 2024-11-07
-$8.03M
10-Q · filed 2024-11-07
2023-06-30-$3.50M
10-Q · filed 2024-08-06
-$5.91M
10-Q · filed 2024-08-06
2023-03-31-$2.41M
10-Q · filed 2024-05-07
2022-12-31-$10.25M
10-K · filed 2024-03-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
FOXO TECHNOLOGIES INC. (FOXO)United States$0.000B-277.71
OneMedNet Corp (ONMD)$0.042B
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
NRC HEALTH (NRC)United States$0.450B42.50
OmniAb, Inc. (OABI)United States$0.698B-8.05
Absci Corp (ABSI)United States$1.775B-14.92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14